CO2018011355A2 - Composiciones y métodos de vacunación contra virus de dengue en niños y adultos jóvenes - Google Patents

Composiciones y métodos de vacunación contra virus de dengue en niños y adultos jóvenes

Info

Publication number
CO2018011355A2
CO2018011355A2 CONC2018/0011355A CO2018011355A CO2018011355A2 CO 2018011355 A2 CO2018011355 A2 CO 2018011355A2 CO 2018011355 A CO2018011355 A CO 2018011355A CO 2018011355 A2 CO2018011355 A2 CO 2018011355A2
Authority
CO
Colombia
Prior art keywords
dengue
virus
compositions
den
methods
Prior art date
Application number
CONC2018/0011355A
Other languages
English (en)
Inventor
Derek Wallace
John Boslego
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of CO2018011355A2 publication Critical patent/CO2018011355A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C12N2770/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las modalidades en la presente conciernen a composiciones, métodos y usos para inducir una respuesta inmune para los cuatro serotipos de virus de dengue en un niño o adulto joven desde aproximadamente 1 año hasta aproximadamente 20 años de edad. Algunas modalidades conciernen a composiciones que pueden incluir, pero no están limitadas a, quimeras de virus de dengue que, ya sea solas o en combinación con otros constructos, pueden usarse en una composición de vacuna contra los cuatro serotipos de virus de dengue. En ciertas modalidades, las composiciones pueden incluir constructos de más de un serotipo de virus de dengue, tal como virus de dengue-1 (DEN-1), virus de dengue-2 (DEN-2), virus de dengue-3 (DEN-3) y/o virus de dengue-4 (DEN-4), a varias concentraciones o proporciones con el fin de mejorar la protección de infección en niños y adultos jóvenes. En ciertas modalidades, los virus de las formulaciones están limitados a serotipos de virus de dengue. Otras modalidades conciernen a métodos para administrar composiciones inmunogénicas contra virus de dengue que pueden incluir constructos quiméricos de dengue y virus de dengue atenuados, vivos, usando regímenes simples, duales u otros.
CONC2018/0011355A 2016-04-13 2018-10-24 Composiciones y métodos de vacunación contra virus de dengue en niños y adultos jóvenes CO2018011355A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662322167P 2016-04-13 2016-04-13
PCT/IB2017/052160 WO2017179017A1 (en) 2016-04-13 2017-04-13 Compositions and methods of vaccination against dengue virus in children and young adults

Publications (1)

Publication Number Publication Date
CO2018011355A2 true CO2018011355A2 (es) 2018-11-13

Family

ID=58671740

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0011355A CO2018011355A2 (es) 2016-04-13 2018-10-24 Composiciones y métodos de vacunación contra virus de dengue en niños y adultos jóvenes

Country Status (14)

Country Link
US (2) US11007261B2 (es)
EP (1) EP3442571A1 (es)
JP (3) JP2019511533A (es)
KR (1) KR102611235B1 (es)
CN (1) CN109069615A (es)
AU (2) AU2017250696A1 (es)
BR (1) BR112018071087A2 (es)
CA (1) CA3020484A1 (es)
CO (1) CO2018011355A2 (es)
MX (1) MX2018012459A (es)
MY (1) MY192806A (es)
PH (1) PH12018502175A1 (es)
SG (2) SG11201808906RA (es)
WO (1) WO2017179017A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507460PA (en) * 2013-03-15 2015-10-29 Takeda Vaccines Inc Compositions and methods for dengue virus chimeric constructs in vaccines
WO2017179017A1 (en) * 2016-04-13 2017-10-19 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
TWI766876B (zh) 2016-08-03 2022-06-11 美商武田疫苗股份有限公司 用於與經改良之調配物一起穩定黃病毒的組成物及方法
CN117752780A (zh) * 2017-12-07 2024-03-26 默沙东有限责任公司 登革病毒疫苗组合物的制剂
BR112021003962A2 (pt) * 2018-09-05 2021-05-25 Takeda Vaccines, Inc. dose unitária de vacina contra dengue e sua administração
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
JP2023516009A (ja) 2020-02-27 2023-04-17 タケダ ワクチン，インコーポレイテッド ウイルス調製物から宿主細胞ｄｎａを取り除く方法
EP3892737A1 (en) * 2020-04-09 2021-10-13 Takeda Vaccines, Inc. Qualitative and quantitative determination of single virus haplotypes in complex samples
WO2023147342A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
EP4357464A1 (en) * 2022-10-20 2024-04-24 Takeda Vaccines, Inc. A method for detecting the presence of a dengue virus serotype in a sample containing at least one dengue virus serotype
WO2024097725A1 (en) * 2022-11-02 2024-05-10 Takeda Vaccines, Inc. A method for determining the infectivity of a virus
WO2024108087A1 (en) 2022-11-18 2024-05-23 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1554301T1 (sl) * 2002-05-03 2011-01-31 Us Health VAKCINA ZA DENGO, KI VSEBUJE SKUPNO DELECIJO 30 NUKLEOTIDOV V 3ĹľUTR TIPOV 1 IN 2 DENGE
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CN107913406A (zh) 2009-06-01 2018-04-17 武田疫苗公司 施用针对登革病毒的疫苗的组合物和方法
CA2915027A1 (en) * 2012-06-10 2013-12-19 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
MY197723A (en) * 2012-07-24 2023-07-10 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
TW201428101A (zh) * 2012-11-08 2014-07-16 Inviragen Inc 登革熱病毒血清型４型之建構物的組成物、方法及用途
EP2931310A4 (en) 2012-12-14 2016-05-25 Takeda Vaccines Inc COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS
SG11201507460PA (en) 2013-03-15 2015-10-29 Takeda Vaccines Inc Compositions and methods for dengue virus chimeric constructs in vaccines
TW201620546A (zh) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 疫苗組合物
WO2017179017A1 (en) * 2016-04-13 2017-10-19 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
BR112021003962A2 (pt) * 2018-09-05 2021-05-25 Takeda Vaccines, Inc. dose unitária de vacina contra dengue e sua administração
US11464815B2 (en) * 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Also Published As

Publication number Publication date
JP2024071463A (ja) 2024-05-24
SG11201808906RA (en) 2018-11-29
AU2018267542B2 (en) 2020-06-18
EP3442571A1 (en) 2019-02-20
BR112018071087A2 (pt) 2019-02-26
MY192806A (en) 2022-09-09
SG10201913383RA (en) 2020-03-30
KR102611235B1 (ko) 2023-12-08
US11007261B2 (en) 2021-05-18
US20210236620A1 (en) 2021-08-05
CN109069615A (zh) 2018-12-21
JP2022089964A (ja) 2022-06-16
CA3020484A1 (en) 2017-10-19
MX2018012459A (es) 2019-06-06
JP2019511533A (ja) 2019-04-25
KR20180137514A (ko) 2018-12-27
WO2017179017A1 (en) 2017-10-19
AU2017250696A1 (en) 2018-11-22
US20190381163A1 (en) 2019-12-19
AU2018267542A1 (en) 2018-12-13
PH12018502175A1 (en) 2019-10-28

Similar Documents

Publication Publication Date Title
CO2018011355A2 (es) Composiciones y métodos de vacunación contra virus de dengue en niños y adultos jóvenes
AR093421A1 (es) Composiciones, metodos y usos de construcciones de virus del dengue de serotipo-4
Khetarpal et al. Dengue fever: causes, complications, and vaccine strategies
ECSP23013715A (es) Composiciones y métodos de construcciones quiméricas del virus del dengue en vacunas
PE20140646A1 (es) Vacuna de virus de dengue inactivado
Torres-Flores et al. Dengue vaccines: an update
JP2019511533A5 (es)
MX336687B (es) Tratamiento y prevencion de infecciones del virus del dengue.
Guy et al. Dengue vaccine prospects: a step forward
MX2018010958A (es) Vacuna para virus de zika atenuado vivo.
PH12016502431A1 (en) Composition and methods for administration of vaccines against dengue virus
JP2016513970A5 (es)
JP2016504315A5 (es)
ATE419006T1 (de) Multivalenter dengue-virus impfstoff
JP2019511221A5 (es)
BR112016002354A2 (pt) composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit
Shah et al. Zika virus infection and development of a murine model
PH12021550785A1 (en) Virus vaccine
BR112016029201A2 (pt) vírus do oeste do nilo/dengue quiméricos e métodos de uso
Huang et al. Vaccine development for mosquito-borne viral diseases
Abrão et al. Dengue vaccines: what we know, what has been done, but what does the future hold?
Pulmanausahakul et al. The development of flavivirus vaccines
Doets et al. Subgenomic flavivirus RNA as key target for live-attenuated vaccine development
Stovba et al. Using the vaccinia virus MVA strain for developing recombinant vector vaccines against current arboviral infections
BR0010969A (pt) Vacina polivalente antivìrus da dengue